These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 38548414)
1. Neoantigen identification: Technological advances and challenges. Pu T; Peddle A; Zhu J; Tejpar S; Verbandt S Methods Cell Biol; 2024; 183():265-302. PubMed ID: 38548414 [TBL] [Abstract][Full Text] [Related]
2. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation. Borden ES; Buetow KH; Wilson MA; Hastings KT Front Oncol; 2022; 12():836821. PubMed ID: 35311072 [TBL] [Abstract][Full Text] [Related]
3. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166 [TBL] [Abstract][Full Text] [Related]
4. Neoantigens: promising targets for cancer therapy. Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431 [TBL] [Abstract][Full Text] [Related]
5. Computational Prediction and Validation of Tumor-Associated Neoantigens. Roudko V; Greenbaum B; Bhardwaj N Front Immunol; 2020; 11():27. PubMed ID: 32117226 [TBL] [Abstract][Full Text] [Related]
6. Engineering neoantigen vaccines to improve cancer personalized immunotherapy. Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174 [TBL] [Abstract][Full Text] [Related]
8. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy. Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE Front Immunol; 2023; 14():1301100. PubMed ID: 38149253 [TBL] [Abstract][Full Text] [Related]
9. Neoantigens in precision cancer immunotherapy: from identification to clinical applications. Zhang Q; Jia Q; Zhang J; Zhu B Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545 [TBL] [Abstract][Full Text] [Related]
10. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy. Ren Y; Yue Y; Li X; Weng S; Xu H; Liu L; Cheng Q; Luo P; Zhang T; Liu Z; Han X Int Immunopharmacol; 2024 Dec; 142(Pt A):113147. PubMed ID: 39270345 [TBL] [Abstract][Full Text] [Related]
11. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines. Pounraj S; Chen S; Ma L; Mazzieri R; Dolcetti R; Rehm BHA Cancer Res; 2024 Feb; 84(3):353-363. PubMed ID: 38055891 [TBL] [Abstract][Full Text] [Related]
12. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255 [TBL] [Abstract][Full Text] [Related]
13. The neoantigens derived from transposable elements - A hidden treasure for cancer immunotherapy. Hu Z; Guo X; Li Z; Meng Z; Huang S Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189126. PubMed ID: 38849060 [TBL] [Abstract][Full Text] [Related]
14. Best practices for bioinformatic characterization of neoantigens for clinical utility. Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330 [TBL] [Abstract][Full Text] [Related]
15. Methods behind neoantigen prediction for personalized anticancer vaccines. Godazandeh K; Van Olmen L; Van Oudenhove L; Lefever S; Bogaert C; Fant B Methods Cell Biol; 2024; 183():161-186. PubMed ID: 38548411 [TBL] [Abstract][Full Text] [Related]
16. Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy. Wu T; Chen J; Diao K; Wang G; Wang J; Yao H; Liu XS Database (Oxford); 2023 Jun; 2023():. PubMed ID: 37311149 [TBL] [Abstract][Full Text] [Related]
17. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy. Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173 [TBL] [Abstract][Full Text] [Related]
18. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction. Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066 [TBL] [Abstract][Full Text] [Related]
19. A proteogenomic approach to target neoantigens in solid tumors. Verma A; Halder A; Marathe S; Purwar R; Srivastava S Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499 [TBL] [Abstract][Full Text] [Related]
20. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Kiyotani K; Chan HT; Nakamura Y Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]